Breast Cancer

21-Gene Genomic Testing Assay May Predict Benefit in Select Young Women With ER+ Early Breast Cancer

July 14, 2020

In an interview with Targeted Oncology, Ann H. Partridge, MD, MPH, discussed the response to neoadjuvant chemotherapy among patients with ER-positive, HER2-negative breast cancer and how the 21-gene Breast Recurrence Score aids in the prediction of response for this treatment.

F-627 Induces Lasting Benefit as Treatment of Chemotherapy-Induced Neutropenia in Breast Cancer

July 10, 2020

Based on phase 3 findings, F-627 appears at least as efficacious and safe as pegfilgrastim, which is the current standard of care, demonstrating strong and durable benefit in patients with breast cancer.

Phase 3 Study Findings Show the Importance of T-DM1 in Early-Stage Breast Cancer

July 10, 2020

In an interview with Targeted Oncology, Julie R. Gralow, MD, discussed the findings from the KAITLIN study of T-DM1 in early-stage breast cancer.

Body Mass Index May Impact Docetaxel-Based Treatment Regimens in Breast Cancer

July 09, 2020

“By retrospectively analyzing data from the adjuvant BIG 2-98 trial, we demonstrated that overweight and obese patients treated with a docetaxel-based chemotherapy regimen presented with a worse disease-free and overall survival compared with average weight patients treated with the same chemotherapy regimen."

Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

July 07, 2020

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Sacituzumab Govitecan Demonstrates Further Survival Efficacy in mTNBC

July 06, 2020

"The results of the global phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC."

COVID-19 Death Toll in NYC Calls Attention to Racial Disparities

July 02, 2020

In New York City, high cases of COVID-19 continue to be reported with a high prevalence among racial and ethnic minorities.

Combination Immunotherapy Appears Promising in Breast Cancer Subtypes

June 25, 2020

Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.

Investigating How to Help Patients With Breast Cancer Stay on Therapy

June 25, 2020

Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.

Atezolizumab Plus Chemotherapy Improves Responses in Triple-Negative Breast Cancer

June 18, 2020

IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.